CXCL2, C-X-C motif chemokine ligand 2, 2920

N. diseases: 186; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.260 Biomarker disease BEFREE Given the bioactivities of MIP-1 alpha and beta and MIP-2 and the recent studies demonstrating their association with lung inflammation, it is likely these chemokines play a significant role in respiratory tract defenses and may contribute to the pathogenesis of inflammatory lung disease. 7882902 1995
CUI: C0024115
Disease: Lung diseases
Lung diseases 		0.210 Biomarker group BEFREE Given the bioactivities of MIP-1 alpha and beta and MIP-2 and the recent studies demonstrating their association with lung inflammation, it is likely these chemokines play a significant role in respiratory tract defenses and may contribute to the pathogenesis of inflammatory lung disease. 7882902 1995
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE To study the effect of localised secretion of chemokines on tumour growth, the genes for human (hu) interleukin 8 (IL-8), hu-MCP-1 (MCAF), hu-MIP-1 alpha (LD78), murine (mu)-MCP-1 (JE), mu-MIP-1 alpha or mu-MIP-2 were introduced, via mammalian expression vectors, into Chinese hamster ovary (CHO) cells, and the ability of transfected cells to form tumours in vivo was evaluated. 7669585 1995
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE The incidence of the tumor reached about 40% when the rats were 12 months old. mRNAs of both pX and host genes Gro and MIP-2, which are granulocyte chemoattractants of the interleukin 8 family, were highly expressed in the tumor tissue. 7780962 1995
CUI: C3714636
Disease: Pneumonitis
Pneumonitis 		0.070 Biomarker disease BEFREE Given the bioactivities of MIP-1 alpha and beta and MIP-2 and the recent studies demonstrating their association with lung inflammation, it is likely these chemokines play a significant role in respiratory tract defenses and may contribute to the pathogenesis of inflammatory lung disease. 7882902 1995
CUI: C0023896
Disease: Alcoholic Liver Diseases
Alcoholic Liver Diseases 		0.200 Biomarker group RGD Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. 10498645 1999
CUI: C0035126
Disease: Reperfusion Injury
Reperfusion Injury 		0.500 Biomarker disease RGD The ratio of ELR+ to ELR- CXC chemokines affects the lung and liver injury following hepatic ischemia/ reperfusion in the rat. 10655268 2000
CUI: C0004626
Disease: Pneumonia, Bacterial
Pneumonia, Bacterial 		0.200 Biomarker group RGD Role of cytokine-induced neutrophil chemoattractant-2 (CINC-2) alpha in a rat model of chronic bronchopulmonary infections with Pseudomonas aeruginosa. 11052817 2000
CUI: C0035126
Disease: Reperfusion Injury
Reperfusion Injury 		0.500 Biomarker disease RGD Lung and liver injury following hepatic ischemia/reperfusion in the rat is increased by exogenous lipopolysaccharide which also increases hepatic TNF production in vivo and in vitro. 11580116 2001
CUI: C0027055
Disease: Myocardial Reperfusion Injury
Myocardial Reperfusion Injury 		0.200 Biomarker phenotype RGD Ischemia-reperfusion of rat myocardium activates nuclear factor-KappaB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. 11342480 2001
CUI: C0025202
Disease: melanoma
melanoma 		0.010 Biomarker disease BEFREE After treatment of mice with 7,12-dimethylbenz(a)anthracene, cutaneous melanomas formed in 12% (17/145) of the Tyr-MIP-2 transgene-positive mice, whereas only 2% (3/146) of the Tyr-MIP-2 transgene-negative mice developed melanoma. 11719444 2001
CUI: C0375023
Disease: Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site 		0.010 AlteredExpression disease BEFREE In this study, we demonstrate that intranasal infection of BALB/c mice with RSV A results in inducible expression of lung chemokines belonging to the CXC (MIP-2 and IP-10), CC (RANTES, eotaxin, MIP-1beta, MIP-1alpha, MCP-1, TCA-3) and C (lymphotactin) families. 11134301 2001
CUI: C0035126
Disease: Reperfusion Injury
Reperfusion Injury 		0.500 Biomarker disease CTD_human Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. 12468449 2002
CUI: C0238281
Disease: Middle Cerebral Artery Syndrome
Middle Cerebral Artery Syndrome 		0.300 Biomarker phenotype CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0740376
Disease: Middle Cerebral Artery Thrombosis
Middle Cerebral Artery Thrombosis 		0.300 Biomarker disease CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.300 Biomarker disease CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0740392
Disease: Infarction, Middle Cerebral Artery
Infarction, Middle Cerebral Artery 		0.300 Biomarker disease CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0751845
Disease: Middle Cerebral Artery Embolus
Middle Cerebral Artery Embolus 		0.300 Biomarker phenotype CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0751846
Disease: Left Middle Cerebral Artery Infarction
Left Middle Cerebral Artery Infarction 		0.300 Biomarker phenotype CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0751847
Disease: Embolic Infarction, Middle Cerebral Artery
Embolic Infarction, Middle Cerebral Artery 		0.300 Biomarker phenotype CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0751848
Disease: Thrombotic Infarction, Middle Cerebral Artery
Thrombotic Infarction, Middle Cerebral Artery 		0.300 Biomarker phenotype CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0751849
Disease: Right Middle Cerebral Artery Infarction
Right Middle Cerebral Artery Infarction 		0.300 Biomarker phenotype CTD_human A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 12374626 2002
CUI: C0520575
Disease: Acute pyelonephritis
Acute pyelonephritis 		0.010 AlteredExpression disease BEFREE The aim of the present study was to investigate the effects of IL-1beta and Escherichia coli on the expression and secretion of MIP-2, the mouse equivalent to human IL-8, MCP-1 and RANTES in the kidneys of mice with acute pyelonephritis. 12562381 2003
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.330 Biomarker disease CTD_human While these differences may represent differential behaviour of synovial fibroblasts in in vitro culture, these observations suggest that TFPI2, GRObeta (CXCL2), MnSOD and GCP-2 (CXCL6) may represent new targets for treatments specifically tailored to osteoarthritis. 15292528 2004
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.330 Biomarker disease BEFREE While these differences may represent differential behaviour of synovial fibroblasts in in vitro culture, these observations suggest that TFPI2, GRObeta (CXCL2), MnSOD and GCP-2 (CXCL6) may represent new targets for treatments specifically tailored to osteoarthritis. 15292528 2004